These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16321620)

  • 1. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.
    Lindh JD; Lundgren S; Holm L; Alfredsson L; Rane A
    Clin Pharmacol Ther; 2005 Nov; 78(5):540-50. PubMed ID: 16321620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
    Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
    Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.
    Goto T; Miura M; Murata A; Terata K; Uno T; Yamamoto K; Abe Y
    Clin Chim Acta; 2010 Sep; 411(17-18):1375-7. PubMed ID: 20420818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.
    Yildirim H; Tamer L; Sucu N; Atik U
    Med Princ Pract; 2008; 17(6):464-7. PubMed ID: 18836275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
    Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
    Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Warfarin in the treatment of antiphospholipid syndrome].
    Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
    Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
    Siddiqi A; Khan DA; Khan FA; Naveed AK
    Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.
    Caraco Y; Blotnick S; Muszkat M
    Clin Pharmacol Ther; 2008 Mar; 83(3):460-70. PubMed ID: 17851566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
    Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
    Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
    Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
    Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation].
    Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
    Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical factors influencing the sensitivity to warfarin when restarted after surgery.
    Schulman S; El Bouazzaoui B; Eikelboom JW; Zondag M
    J Intern Med; 2008 Apr; 263(4):412-9. PubMed ID: 18205763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
    Ruud E; Holmstrøm H; Bergan S; Wesenberg F
    Pediatr Blood Cancer; 2008 Mar; 50(3):710-3. PubMed ID: 17226852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
    Muszkat M; Bialer O; Blotnick S; Adar L; Xie HG; Ufer M; Cascorbi I; Caraco Y
    Clin Ther; 2010 Feb; 32(2):347-56. PubMed ID: 20206792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
    JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
    Gschwind L; Rollason V; Boehlen F; Rebsamen M; Combescure C; Grünenwald M; Matthey A; Bonnabry P; Dayer P; Desmeules JA
    Pharmacogenomics; 2013 May; 14(7):745-53. PubMed ID: 23651023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.